Online pharmacy Valisure on June 13 issued a letter to the FDA after in-house testing revealed dangerously elevated levels of N,N-Dimethylformamide (DMF) in certain lots of valsartan, an angiotensin II receptor blocker (ARB) commonly used to treat hypertension and heart failure.
Global 3D printing company Materialise on June 13 announced its Mimics Enlight cardiovascular planning software suite received FDA clearance and will soon be rolled out to clinicians.
Inadequate fruit and vegetable consumption contributes to nearly 2 million CV-related deaths each year, according to research presented at Nutrition 2019, the American Society for Nutrition’s annual meeting, in Baltimore.
North Carolina Children’s Hospital will be suspending heart surgeries for its most complex cases for the time being—a direct response to a New York Times investigation that called into question the safety of practices in the center’s pediatric heart surgery unit—the Times reported June 17.
The antihypertensive drug nilvadipine may benefit Alzheimer’s patients by encouraging blood flow to the brain, slowing the progression of the disease while reducing blood pressure in the hippocampus, researchers reported in Hypertension June 17.
With a recent rise in heart-attack related deaths among Americans vacationing overseas, one domestic cardiologist is speaking up about CV health while traveling.
A 25-minute steam in the sauna could be just as beneficial for heart health as a moderate physical workout, researchers at Martin Luther University Halle-Wittenberg and the Medical Center Berlin have found.
Cardiologists’ salaries are up, their savings are steady and their debt is minimal, according to Medscape’s annual Cardiologist Wealth and Debt Report.
An eight-day trial and two-hour jury deliberation has culminated in the conviction of Pennsylvania cardiologist Samirkumar J. Shah, who on June 14 was found guilty of two counts of healthcare fraud for falsely billing insurers for unnecessary angina treatments.
Research presented at TVT 2019 in Chicago last week suggests a transcarotid approach to transcatheter aortic valve replacement is favorable for patients unable to tolerate femoral access, topping both transapical and transaortic approaches as the preferable route for alternate-access TAVR.